Judge limits Mallinckrodts damages in patent infringement suit

Justine Varieur Cadet | | Health Exec | Precision Medicine
A federal judge has cut the potential damages Covidien's Mallinckrodt subsidiary can receive in its patent infringement case over medical injectors against two U.S. divisions of Bracco—Lake Success, N.Y.-based E-Z-EM and Acist Medical Systems of Eden Prairie, Minn.

Judge T. John Ward of the U.S. District Court for the Eastern District of Texas Tuesday prohibited the plaintiffs from seeking damages for indirect infringement based on the sale of syringes for use with power injectors that occurred before the suit’s filing in 2007.

He ruled that the patent in question does not cover injectors that the companies made before that date. Hazelwood, Mo.-based Mallinckrodt sued the companies for infringing its patent over MRI power injectors.

Mallinckrodt, a division of the Dublin Ireland-based Covidien, wants a jury trial, unspecified damages and an injunction to prevent further infringement by the Bracco divisions' Empower devices.

Justine Varieur Cadet

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

AI in Healthcare
4 points crucial to the nimble regulation of GenAI

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Design by Adaptive Theme
Trimed Popup
Trimed Popup